Comorbidities Are Frequent in Older Patients with De Novo Acute Lymphoblastic Leukemia (ALL) and Correlate with Induction Mortality: Analysis of More Than 1200 Patients from GMALL Data Bases (2018) Wermann WK, Viardot A, Kayser S, Alakel N, Elmaagacli A, Faul C, Fiedler W, et al. Conference contribution Nilotinib Vs Nilotinib Plus Pegylated Interferon-alpha2b Induction and Nilotinib or Pegylated Interferon-alpha2b Maintenance Therapy for Newly Diagnosed BCR-ABL plus Chronic Myeloid Leukemia Patients in Chronic Phase: Interim Analysis of the Tiger (CML V)-Study (2018) Hochhaus A, Saussele S, Baerlocher GM, Bruemmendorf TH, Burchert A, La Rosee P, Hasford J, et al. Conference contribution MOR202 with Low-Dose Dexamethasone (Dex) or Pomalidomide/Dex or Lenalidomide/Dex in Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis of a Phase I/IIa, Multicenter, Dose-Escalation Study (2018) Raab MS, Chatterjee M, Goldschmidt H, Agis H, Blau I, Einsele H, Engelhardt M, et al. Conference contribution Prolyl Hydroxylase 3 (Phd3) Is a Therapeutic Target in Isocitrate Dehydrogenase 1 (IDH1) Mutated Acute Myeloid Leukemia (2018) Chaturvedi A, Cruz MMA, Goparaju R, Gabdoulline R, Schottmann R, Goerlich K, Kloos A, et al. Conference contribution DNA Damage-Response Pathway in Lymphoma Determines Interactions with Macrophages By Altered PD-Li Expression and Fxosome Formation (2018) Vorholt D, Izquierdo-Alvarez E, Sackey B, Schmitz J, Nickel N, Blakemore S, Knittel G, et al. Conference contribution Myc-Driven, Primary Mouse Lymphoma Expressing Human CD22 Are Highly Infiltrated By Syngeneic Immune Cells and Provide a Unique Model to Test CD22-Targeted Therapies (2018) Wagner F, Brandl C, Emmerich C, Mackensen A, Nitschke L, Müller F Conference contribution Prospective Clinical Phase II Results on Treosulfan-Based Conditioning Treatment of 70 Paediatric Patients with Haematological Malignancies (2018) Kalwak K, Bader P, Styczynski J, Gruhn B, Patrick K, Sedlacek P, Stachel D, et al. Conference contribution Role of N6-Methyladenosine (m6A) RNA Modification in Multiple Myeloma (2018) Bach C, Leffler M, Flamann C, Kronke J, Mougiakakos D, Mackensen A, Bruns H Conference contribution Invariant Natural Killer T Cells from Donor Lymphocyte Infusions (DLI-iNKTs) Contribute to Anti-Tumor Immunity after Allogeneic Hematopoietic Cell Transplantation (2018) Jahnke S, Schmid H, Secker KA, Duerr-Stoerzer S, Keppeler H, Schumm M, Handgretinger R, et al. Conference contribution Stroma Cells Promote a S100A8/A9(high)-Subset of AML Blasts with Distinct Metabolic Features in a Jak/STAT3-Dependent Manner (2018) Böttcher M, Panagiotidis K, Mackensen A, Mougiakakos D Conference contribution